Losartan Compounding Legal Status

When Was Losartan FDA Approved and What Is Its Regulatory History?

Losartan (brand name Cozaar) received FDA approval on April 14, 1995, making it the first orally active angiotensin II receptor blocker approved in the United States. Merck submitted NDA 020386, and the drug was cleared for the treatment of hypertension in adults. Two subsequent supplemental NDAs expanded the label to include reduction of stroke risk in hypertensive patients with left ventricular hypertrophy and the treatment of diabetic nephropathy in patients with type 2 diabetes and proteinuria.

The Path From Brand to Generic

Patent exclusivity on Cozaar expired in April 2010. Within months, the FDA approved multiple Abbreviated New Drug Applications (ANDAs) from generic manufacturers, and by mid-2010 losartan potassium tablets were available in 25 mg, 50 mg, and 100 mg strengths from more than a dozen manufacturers. This generic competition drove the retail price of a 30-day supply below $10 at most pharmacies, fundamentally changing the compounding calculus.

Fixed-Dose Combination Approvals

The FDA also approved losartan potassium 50 mg/hydrochlorothiazide 12.5 mg and a 100 mg/25 mg fixed-dose combination (Hyzaar, NDA 020387) in 1995, with generics following after 2010. An oral suspension formulation (Cozaar 2.5 mg/mL) was later approved for pediatric patients who cannot swallow tablets, a point that becomes relevant when evaluating whether compounding a liquid losartan preparation is legally defensible.

The FDA's Drugs@FDA database entry for NDA 020386 confirms the current approval status and lists all approved strengths and labeling documents. [1]

What Does the Losartan FDA Label Say?

The current FDA-approved prescribing information for losartan is a legally binding document that specifies indications, contraindications, warnings, dosing, and population-specific guidance. Prescribers and compounding pharmacists must understand the label before making any dispensing decisions.

Approved Indications

The label lists three indications:

1. Hypertension in adults and pediatric patients 6 years and older.
2. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. The label explicitly notes that this benefit does not apply to Black patients, based on the LIFE trial subgroup analysis.
3. Diabetic nephropathy with elevated serum creatinine and proteinuria (urinary albumin/creatinine ratio above 300 mg/g) in patients with type 2 diabetes and hypertension.

Black Box Warning: Fetal Toxicity

The prescribing information carries a Black Box Warning stating that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. The label instructs prescribers to discontinue losartan as soon as pregnancy is detected. [2] This warning applies equally to any compounded losartan preparation, and a compounding pharmacy cannot legally omit or modify this warning language.

Key Dosing Parameters

• Adults with hypertension: 50 mg once daily as the starting dose, with a range of 25 mg to 100 mg daily in one or two divided doses.
• Patients with intravascular volume depletion or hepatic impairment: start at 25 mg once daily.
• Pediatric patients (6 years and older, weight at least 20 kg): 0.7 mg/kg once daily, up to 50 mg total.
• Pediatric patients weighing more than 50 kg: up to 100 mg daily.

The label notes that losartan is not recommended for pediatric patients with a glomerular filtration rate below 30 mL/min/1.73 m², a clinical detail that shapes whether a compounded liquid formulation for a child might be considered medically necessary. [1]

What Is the Legal Status of Compounded Losartan?

Compounded losartan occupies a legally constrained position. Because FDA-approved losartan products exist in multiple commercially available strengths and formulations, the routine compounding of losartan for cost or convenience reasons conflicts with federal law under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Section 503A: Traditional Compounding Pharmacies

Under Section 503A of the FD&C Act, a licensed pharmacist may compound a drug product for an identified individual patient based on a valid prescription if certain conditions are met. One of those conditions is that the compounded drug cannot be essentially a copy of a commercially available product. [3]

The FDA's guidance on what constitutes an "essentially a copy" has been litigated and clarified in multiple court decisions. For losartan, the analysis turns on whether the prescribed preparation differs meaningfully from an approved product. A simple 50 mg capsule made from losartan powder, for a patient who could swallow the commercially available tablet, would almost certainly be considered an essentially-a-copy preparation and therefore impermissible under 503A.

However, there are narrow exceptions. The statute permits compounding an essentially-a-copy product if the prescriber documents a clinical difference, meaning a specific difference from the commercially available drug that produces a significant difference for the patient. Examples that might qualify:

• A patient with a documented allergy to an excipient present in all commercially available losartan tablets (such as microcrystalline cellulose or lactose).
• A patient requiring an oral liquid at a concentration not commercially available and who cannot swallow any solid dosage form (though the FDA-approved 2.5 mg/mL suspension complicates this argument for most patients).
• A patient requiring a dose that cannot be achieved by splitting or combining approved tablets.

Even in these cases, the prescriber must document the clinical rationale in writing, and the compounding pharmacy remains responsible for ensuring compliance with USP Chapter 795 standards. [3]

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities can compound drugs without individual prescriptions for hospital or clinic use, but only under specific conditions. A drug on the FDA's 503B Bulks List or produced from an approved drug during a shortage may be compounded at scale. Losartan does not appear on the FDA's current 503B Bulks List, and there is no active FDA drug shortage designation for losartan as of early 2025. [4]

This means a 503B facility compounding large batches of losartan for distribution to clinics lacks the legal authorization that semaglutide, for example, had during its shortage period. The analogy matters because some telehealth platforms marketing "customized" antihypertensive regimens have attempted to apply the GLP-1 shortage compounding model to other drug classes, including ARBs. That approach does not hold legal water for losartan under current FDA policy.

The Shortage Exception: Past and Present

Losartan was listed on the FDA Drug Shortage database from approximately 2019 through early 2020 due to manufacturing contamination issues related to N-nitrosodiethylamine (NDEA) impurities found in losartan active pharmaceutical ingredient sourced from several overseas manufacturers. [5] During that window, compounding pharmacies had somewhat more latitude.

The FDA's shortage designation has since been resolved. Supply is currently adequate across all approved strengths and manufacturers. A compounding pharmacy relying on the shortage exception for losartan today would be operating outside current regulatory guidance.

The HealthRX Compounding Eligibility Framework for ARBs (developed by the HealthRX medical and compliance teams) classifies losartan as a Tier 3 drug: commercially available, no active shortage, compounding permissible only with documented excipient allergy or clinically necessary dose customization that cannot be achieved with approved products. This framework guides prescriber decision-making during patient intake and is distinct from the GLP-1 Tier 1 classification that applied to semaglutide during its 2022-2024 shortage.

What Does the LIFE Trial Tell Us About Losartan's Clinical Evidence Base?

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, published in The Lancet in 2002, remains the most cited piece of outcome evidence for losartan and directly shaped the stroke-risk indication on the FDA label. [6]

Trial Design and Population

LIFE enrolled 9,193 patients aged 55 to 80 years with hypertension and electrocardiographic evidence of left ventricular hypertrophy. Patients were randomized to losartan 50 mg or atenolol 50 mg, with dose titration and hydrochlorothiazide add-on permitted to achieve a blood pressure target below 140/90 mmHg.

Primary Endpoint Results

After a mean follow-up of 4.8 years, losartan reduced the primary composite endpoint (cardiovascular death, myocardial infarction, or stroke) by 13% compared with atenolol (relative risk 0.87, 95% CI 0.77 to 0.98, P = 0.021). [6] The benefit was driven predominantly by a 25% reduction in fatal and non-fatal stroke (relative risk 0.75, 95% CI 0.63 to 0.89, P<0.001).

Blood pressure control was nearly identical between groups, suggesting the stroke reduction reflected an effect beyond blood pressure lowering, possibly related to losartan's regression of left ventricular hypertrophy.

The Black Patient Subgroup Finding

In the pre-specified subgroup of 533 Black patients, atenolol was associated with a lower rate of the primary composite endpoint than losartan (relative risk for losartan vs. Atenolol 1.60, 95% CI 1.05 to 2.44). [6] This finding is the basis for the label statement that the stroke-risk reduction benefit does not apply to Black patients. It does not affect the hypertension or nephropathy indications, and guidelines continue to recommend ARBs for Black patients with diabetic nephropathy or with a compelling indication such as heart failure.

Diabetic Nephropathy Evidence

The RENAAL trial (N = 1,513) showed losartan 100 mg daily reduced the risk of the composite endpoint of doubling of serum creatinine, end-stage renal disease, or death by 16% compared with placebo in patients with type 2 diabetes and nephropathy. [7] This trial supported the third indication on the losartan label.

Losartan Safety Profile: Post-Market Surveillance and Known Risks

The FDA Sentinel System monitors post-market safety signals across a distributed network of electronic health records and insurance claims databases covering more than 100 million patients. Several losartan safety signals have been evaluated through Sentinel or predecessor programs.

Nitrosamine Contamination: The 2018-2020 Recall Events

Starting in July 2018, the FDA began receiving reports of NDMA (N-nitrosodimethylamine) and NDEA contamination in valsartan API sourced from Zhejiang Huahai Pharmaceutical. Subsequent testing identified NDEA contamination in losartan API from multiple manufacturers by early 2019. [5]

The FDA issued multiple Class II recalls of losartan tablets between March 2019 and 2020. The agency set an acceptable daily intake limit for NDEA in losartan products at 0.0083 micrograms per day. Products exceeding this limit were recalled while reformulated supply chains were established.

This contamination event has direct relevance to compounding: some compounding pharmacies attempted to position their preparations as contamination-free alternatives during the recall period. The FDA issued warning letters to several facilities making unsubstantiated contamination-free claims without adequate API testing documentation.

Hyperkalemia Risk

The label warns that losartan can cause hyperkalemia, particularly in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics, potassium supplements, or other drugs that raise serum potassium. A 2016 analysis using the FDA Adverse Event Reporting System (FAERS) identified hyperkalemia as a disproportionately reported event with ARBs as a class. [8] Baseline potassium and renal function testing before initiating losartan, and monitoring at 1 to 2 weeks after any dose increase, is standard clinical practice.

Renal Function Deterioration

Dual blockade of the renin-angiotensin system (combining losartan with an ACE inhibitor or aliskiren) was evaluated in the ONTARGET trial and found to increase the risk of renal impairment, hypotension, and hyperkalemia without additional cardiovascular benefit. [9] The FDA updated the labels of ARBs and ACE inhibitors to contraindicate dual blockade in patients with diabetic nephropathy following this evidence.

Drug Interactions of Clinical Note

• Lithium: Losartan reduces lithium renal clearance. Monitor lithium levels closely.
• NSAIDs: Can attenuate the antihypertensive effect and worsen renal function, particularly in elderly or volume-depleted patients.
• CYP2C9 inhibitors (fluconazole, for example): Losartan is metabolized to its active metabolite E-3174 by CYP2C9. Inhibitors of this enzyme reduce conversion to E-3174 and may reduce efficacy. Inducers (rifampin) may reduce losartan exposure.
• Potassium-raising agents: Trimethoprim, heparin, and direct renin inhibitors all compound hyperkalemia risk.

How Should Prescribers and Patients Approach Compounded Losartan Requests?

Most patients requesting compounded losartan do so for one of three reasons: perceived contamination concerns from the 2019 recall era, cost, or a desire for a non-commercially-available dose or formulation. Each requires a distinct clinical and regulatory response.

Contamination Concerns

The nitrosamine contamination issue that triggered the 2019 to 2020 recalls has been addressed. The FDA now requires losartan manufacturers to test for nitrosamine impurities under the 2021 guidance for industry on nitrosamine drug substance-related impurities. [10] Commercially available losartan from licensed manufacturers is subject to these controls. A compounding pharmacy is not inherently safer than a licensed pharmaceutical manufacturer; in fact, USP 795 compounding facilities are not required to meet the same process validation or analytical testing standards as current Good Manufacturing Practice (cGMP) facilities.

Cost-Based Requests

Generic losartan 50 mg tablets retail for approximately $4 to $9 per 30-day supply at major pharmacy chains with GoodRx or equivalent discount programs. Compounded losartan would typically cost more, not less, than generic tablets. Cost is not a valid clinical justification for compounding under 503A, and no reputable compounding pharmacy should accept cost as the sole reason.

Dose or Formulation Customization

This is the one area where compounding may have genuine clinical utility. A pediatric patient requiring a dose between 5 mg and 25 mg who cannot use the FDA-approved 2.5 mg/mL suspension due to a documented ingredient intolerance may have a defensible case for a custom preparation. An adult patient requiring, for example, 37.5 mg per day (not achievable by standard tablet splitting) and with documented intolerance to the approved product also represents a potential candidate.

The prescriber must document:

1. The specific commercially available product(s) evaluated and why each is inadequate.
2. The clinical difference the compounded preparation will provide.
3. The compounding pharmacy's name, PCAB accreditation status, and USP 795 compliance documentation.

Guideline Positioning of Losartan in Current Hypertension Management

The 2017 ACC/AHA Hypertension Guidelines list ARBs as a first-line treatment class for hypertension, equivalent to thiazide diuretics, ACE inhibitors, and calcium channel blockers. [11] The guidelines state: "ARBs are recommended as first-line therapy for hypertension in patients with CKD, regardless of race, because of their renoprotective effects." Losartan, as the most extensively studied ARB in CKD outcomes, is specifically referenced in the CKD subpopulation recommendations.

The 2022 AHA/ACC/HFSA Heart Failure Guidelines recommend ARBs for patients with heart failure with reduced ejection fraction (HFrEF) who are ACE inhibitor-intolerant, with a Class I, Level of Evidence A recommendation. [12] Losartan at 50 mg to 150 mg daily is listed among the acceptable agents, though sacubitril/valsartan (an ARB combined with a neprilysin inhibitor) is preferred when tolerated.

Neither set of guidelines addresses compounded losartan, as the availability of generic approved product makes compounding unnecessary for the standard patient population covered by these recommendations.

Regulatory Pathway if Compounding Is Deemed Necessary

If a prescriber and patient reach the conclusion that a compounded losartan preparation is clinically warranted, the following regulatory pathway applies:

Step 1: Document Medical Necessity

The prescription must include a notation explaining why the commercially available product is inadequate. This is not optional under 503A; it protects both the prescriber and the compounding pharmacy in the event of an FDA inspection.

Step 2: Choose a PCAB-Accredited Pharmacy

The Pharmacy Compounding Accreditation Board (PCAB) accreditation signals that a pharmacy meets voluntary quality standards beyond state board minimums. While PCAB accreditation is not legally required, it reduces liability exposure and provides some assurance that the pharmacy tests its preparations for potency, sterility (for any sterile preparations), and absence of contaminants.

Step 3: Confirm API Source

The compounding pharmacy should be able to provide a Certificate of Analysis (CoA) for the losartan API it uses, including nitrosamine testing results. Given the history of contamination in overseas API supply chains, this documentation is clinically and legally relevant.

Step 4: Patient Counseling

Patients receiving compounded losartan must receive the same Black Box Warning about fetal toxicity that appears on the approved product labeling. The prescriber or dispensing pharmacist bears responsibility for ensuring this counseling occurs.